Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ovastadstat + rifampicin
- Development stage
- Unknown
- Lead developer
- Sorrento Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ovastadstat + rifampicin refers to a clinical study regimen used to evaluate the drug-drug interaction between ovastadstat (STI-1558), an oral SARS-CoV-2 main protease (Mpro) inhibitor, and rifampicin, a potent inducer of cytochrome P450 enzymes. Ovastadstat is a small-molecule antiviral developed by Sorrento Therapeutics for the treatment of COVID-19, designed to inhibit the 3CL protease essential for viral replication. Rifampicin is a broad-spectrum antibiotic and a well-characterized inducer of CYP3A4. The co-administration of these agents in Phase 1 clinical trials (such as NCT05510011) is intended to quantify the impact of metabolic induction on the pharmacokinetics of ovastadstat, thereby informing dosing guidelines and identifying potential contraindications for patients receiving concomitant enzyme-inducing medications.
- Other names
- STI-1558 + rifampinovastadstat and rifampicinSTI-1558 and rifampinSTI1558 and rifampinSTI 1558 and rifampinrifampinrifampicinovastadstat
02
Targets
CTSL (Cathepsin L)Mpro (3C-like proteinase of SARS-CoV-2)
Beyond the preview
Go deeper on ovastadstat + rifampicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ovastadstat + rifampicin.